摘要:
A topical formulation for reducing skin irritation in animals is described which comprises about .5 to about 10 % by weight of the total formulation of an aqueous-soluble strontium cation in a suitable topical formulation vehicle. The figure shows experimental data where strontium nitrate is selected as the anti-irritant salt component of the subject formulation.
摘要:
Compositions and methods are provided for inhibiting skin irritation attributable to chemical irritants or environmental conditions, by the application of an anti-irritant amount of aqueous-soluble divalent strontium cation.
摘要:
Es werden biologisch aktive Ertrakte aus Blut, Blutplas ma, Milch, Knorpelsubstanz, Plazenta- und Muskelgewebe, Zerealien, Kartoffeln, Fisch, Eiern, Mikroorganismen, wie Hefe, oder Malz beschrieben, die kurskettige Peptide ent halten. Diese Ertrakte besitzen interessante pharmakologische Eigenschaften und verstärken die Wirkung von bekannten durchblutungsfördernden Wirkstoffen.
摘要:
The invention relates to a plant extract from a food crop residue and sebacic acid or a salt thereof for use in a method of treatment of a fungal infection, said food crop belonging to the family of Solanaceae. The invention further relates to a composition comprising a plant extract from a food crop residue belonging to the family of Solanaceae or sebacic acid and a suitable carrier.
摘要:
Ein Verfahren zur Herstellung eines analogen homöopathischen Wirkstoffes aus einer Trägersubstanz soll folgende Schritte umfassen: - Bereitstellen der Trägersubstanz - Dynamisierung der Trägersubstanz umfassend ein Aufbringen einer elektromagnetischen Strahlung und/oder ein Aufbringen von Schallwellen auf die Trägersubstanz.
摘要:
The present invention concerns food, food supplement and food additive compositions that comprise: (i) a substantially lycopene-free extract of fruit of the Solanaceae family wherein the extract comprises (a) a glycosylated phenolic acid or a phenolic ester, (b) a glycosylated flavonoid, and (c) a nucleoside; and wherein the extract is a powder and contains 95% of the bioactive components (a), (b) and (c) that are contained in a start mix from which the extract is prepared; and (ii) a nutritionally acceptable excipient or food ingredient. The compositions are useful in the treatment or prevention of a medical condition characterised by inappropriate platelet aggregation.